| HOME >> BIOLOGY >> TECHNOLOGY |
-- $208 million, primarily non-cash, associated with the write down of
goodwill in connection with business divestitures;
-- $8 million of other net acquisition-related charges;
-- $365 million attributable to estimated potential losses associated with
patent litigation involving the Company's Interventional Cardiology
business;
-- $184 million of restructuring charges associated with the Company's
expense and head count reduction initiatives; and
-- $174 million of amortization expense.
Adjusted net income for the quarter, excluding these charges and amortization expense, was $355 million, or $0.24 per share.
Reported net income for the fourth quarter of 2006 was $277 million, or $0.19 per share. Reported results included charges associated with the Company's 2006 acquisition of Guidant Corporation and amortization expense (pre-tax) of $197 million, or $0.11 per share. Adjusted net income for the fourth quarter of 2006, excluding these charges and amortization expense, was $442 million, or $0.30 per share.
Full Year 2007
Net sales for the full year 2007 were $8.357 billion, as compared to $7.821 billion in 2006. Worldwide sales of the Company's drug-eluting coronary stent systems were $1.788 billion, as compared to $2.358 billion. U.S. sales of drug-eluting coronary stent systems were $1.006 billion, as compared to $1.561 billion. International sales of drug-eluting coronary stent systems were $782 million, as compared to $797 million. Worldwide sales of coronary stent systems were $2.027 billion, as compared to $2.506 billion. U.S. sales of coronary stent systems were $1.110 billion, as compared to $1.613 billion. International sales of coronary stent systems were $917 million, as compared to $893 million.
Worldwide sales of the Company's CRM business in 2007 were $2.124
billion, which included $1.542 billion of ICD sales, as compared to $1.371
billion in 2006, which
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Boston Scientific to Participate in Merrill Lynch Conference
2. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
3. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
5. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
6. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
7. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
8. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
9. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
10. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
11. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |